Reliis has a clear vision of creating innovative solutions by leveraging safe and effective medicines to address unmet clinical needs, with significant commercial value.
What sets Reliis apart is its strong emphasis on collaboration with renowned medical professionals and clinicians. This distinctive approach, combined with a highly dedicated and knowledgeable team, has established Reliis as an emerging player in the industry.
One of Reliis' key strategies is drug reformulation, which enables a faster and more cost-effective pathway for regulatory approval and commercialisation compared to traditional novel drug development programs. Reliis’ initial product, RLS-Q2201, is a reformulated injectable solution specifically designed to address the urgent unmet clinical need for effective delirium treatment.
Learn more on the Reliis website.
